SeraNovo Enters into License Agreement with Graviton

Leiden, May 5th, 2021: SeraNovo Enters into a License Agreement with Graviton Bioscience Corporation to Develop an Oral Formulation for Graviton’s oncology compound G101.


SeraNovo BV is pleased to announce the closing of a License Agreement with Graviton Bioscience Corporation (Graviton), a biopharmaceutical company engaged in the research and development of small molecules in the fields of oncology and neuroscience. Under the agreement, the companies will expand their existing collaboration and jointly develop a solubility-enhancing formulation for G101 utilising SeraNovo’s proprietary deep eutectic solvent formulation platform.


Niall Hodgins, Chief Executive Officer of SeraNovo commented: “We are pleased to enter into this license agreement with Graviton. Within the framework of this collaboration, we will utilize our deep eutectic solvent technology to develop a formulation that enhances the oral bioavailability of G101 – a problem that many competing technologies have been unable to solve. This newly established relationship with Graviton on a promising but poorly bioavailable active pharmaceutical ingredient (API) provides another important piece of industry validation of our technology. We are excited to continue our expansion into North America and into the oncology field. SeraNovo are looking forward to many fruitful collaborations in these important markets.”


About SeraNovo: SeraNovo is an innovative formulation company improving the oral bioavailability of active pharmaceutical ingredients. The focus of the company is on solving the problem of poor API solubility by designing tailor-made, deep eutectic solvent based formulations to increase oral bioavailability. SeraNovo is a privately owned company located in Leiden, the Netherlands and as technology inventor owns all know-how and IP. For more information, please visit


About Graviton:  Graviton Bioscience Corporation is a biopharmaceutical company focused on the discovery and development of small molecule API to treat serious unmet medical needs in oncology and neurological diseases. For more information, please visit


Forward-Looking StatementsThis press release contains forward-looking statements, including but not limited to statements regarding development plans, the DES Formulation Platform, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law.


For further information, please contact us at

This website uses cookies to track the usage of it.

More info